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INTRODUCTION
Erythropoietin (EPO) has protective ef-
fects and decreases neuroinflammation
in various models of neurological dis-
eases, including traumatic and ischemic
injury of the brain and the spinal cord
and multiple sclerosis (MS) (1,2). Inhibi-
tion of neuronal death and neuroinflam-
mation are important for the protective
effects (3). However, many studies have
pointed out that EPO also promotes neu-
rorepair, in terms of neurogenesis, angio-
genesis and promotion of synaptic plas-
ticity (4–6).
In the context of MS, EPO has antiin-
flammatory (7,8) and immunoregulatory
properties (9,10). In addition, it inhibits
demyelination and axonal damage
(11,12), but it is unclear whether this ef-
fect is secondary to its antiinflammatory
and immunoregulatory action. However,
there are evidences that EPO is effective
also in nonimmune models of demyeli-
nation. EPO is protective in vivo in a
model of chemically induced demyelina-
tion (13) and induces myelin repair in an
ex vivo model of demyelination induced
by lysolecithin (14). Interestingly, EPO
increases the number of myelin basic
protein (MBP)-positive cells in primary
oligodendrocytes (15).
The role of the EPO receptor (EPOR) in
the neuroprotective actions of EPO is a
debated issue (16). EPO mediates ery-
thropoiesis by homodimerizing EPOR
(17) but derivatives of EPO that do not
bind the homodimeric EPOR, and are
therefore not erythropoietic, are still neu-
roprotective (18,19), and EPO can reduce
brain damage in mice lacking neural
EPOR (20). On the other hand, EPOR is
required for normal brain development
(21) and for inhibition of apoptosis in
neuronal cells (22). Also, the observation
that brain EPOR expression is increased
during pathological conditions in hu-
mans, including ischemic infarcts and
hypoxic brain damage, suggests a poten-
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tial protective role of the classical recep-
tor (23). Recent studies have indicated
that the spectrum of actions of EPOR can
go beyond those induced by its homod-
imerization, and the tissue-protective ac-
tivities of EPO might be due, at least in
part, to heterodimerization of EPOR with
the common β chain (bc) of interleukin
(IL)-3/IL-5 and granulocyte-macrophage
colony-stimulating factor (GM-CSF).
EPO variants (for example, carbamylated
EPO, CEPO) that can bind the het-
erodimeric EPOR/bc but not the EPOR
dimer have tissue-protective effects
equivalent to EPO in multiple animal
models of disease (24).
Here, we studied the effect of EPO on
myelination, specifically investigating
the role of EPOR. For this purpose, we
measured the expression of two major
myelin genes, myelin oligodendrocyte
glycoprotein (MOG) and myelin basic
protein (MBP), in the differentiated CG4
oligodendrocytic cell line, with or with-
out EPOR expression. CG4 cells are con-
sidered a good tool to study myelination
in vitro (25,26). We also investigated the
role of early growth response gene 2
(Egr2), a gene required for myelination in
the peripheral nervous system (27),
whose expression is induced by EPO in
the brain (6). The results of this study
clearly indicate that EPOR is required for
EPO-induced myelination.
MATERIALS AND METHODS
Cell Culture and Generation of CG4
Cells Expressing EPOR (CG4-EPOR)
The oligodendrocyte progenitor cell
line CG4 was cultured in poly-L-
 ornithine–coated tissue culture plates
(Sigma-Aldrich, St. Louis, MO, USA).
Cells were maintained at the precursor
stage using growth medium (GM) con-
sisting of Dulbecco’s modified Eagle me-
dium (DMEM) (PAA Laboratories, Yevil,
Sommerset, UK) supplemented with 
biotin (10 ng/mL), bFGF (5 ng/mL),
PDGF (1 ng/mL), N1 supplement (all
from Sigma-Aldrich) and 30% B104-
 conditioned medium. Rat neuroblastoma
B104 cells were cultured in DMEM sup-
plemented with 10% fetal bovine serum
(FBS) (Invitrogen/ Life Technologies,
Carlsbad, CA, USA). For the preparation
of the B104-conditioned medium, B104
confluent cells were cultured for 4 d in
DMEM, without FBS, but with the addi-
tion of N1 supplement. CG4 cells overex-
pressing EPO receptor (CG4-EPOR) were
obtained by transduction of CG4 cells
with the mouse EPOR gene in a constitu-
tive lentiviral vector (28), modified to in-
clude the V5 epitope, the mouse en-
cephalomyocarditis internal ribosome
entry site (IRES) and the enhanced green
fluorescent protein (EGFP) reporter (6,25).
Clones were isolated by limiting dilution,
by plating transduced cells at the concen-
tration of 0.3 cells/well in 96 well plates
in GM, and then screened for EPOR ex-
pression by quantitative polymerase chain
reaction (qPCR), as described below. Con-
trol CG4 cells (CG4-EGFP) were obtained
by transduction of CG4 cells with a
lentiviral vector containing EGFP only.
CG4 cells were induced to differentiate
to oligodendrocytes by switching to dif-
ferentiation medium (DM) consisting of
DMEM-F12 (PAA) supplemented with
progesterone (3 ng/mL), putrescine
(5 μg/mL), sodium selenite (4 ng/mL),
insulin (12.5 μg/mL), transferrin
(50 μg/mL), biotin (10 ng/mL), thyrox-
ine (0.4 μg/mL) and glucose (3 g/L) (all
from Sigma-Aldrich). Cells were treated
with recombinant human erythropoietin
(rhEPO) (Creative Dynamics, New York,
NY, USA) at the doses indicated. Car-
bamylated EPO (CEPO), prepared as de-
scribed (18), was kindly supplied by
Warren Pharmaceuticals, Ossining, NY,
USA.
EPOR Expression in CG4-EPOR Cells
The expression of recombinant V5-
tagged EPOR in transduced CG4 cells
was verified by measuring by flow cy-
tometry the EGFP reporter expression, as
well as by immunoblotting with the anti-
V5-tag mouse monoclonal antibody (In-
vitrogen/Life Technologies), as described
(6,25). EGFP, whose translation is linked
to EPOR via the internal ribosome entry
site (IRES), is a very reliable marker of
the gene of interest expression when bi-
cistronic vectors are used (25).
Quantitative PCR
Total RNA was extracted from cultured
cells using TRIzol (Invitrogen/Life Tech-
nologies). RNA quality and concentration
were determined using a  NanoDrop ND-
1000 (NanoDrop Technologies/ Thermo
Fisher Scientific, Wilmington, DE, USA).
Reverse transcription and real-time
qPCR were carried out as reported (6),
using TaqMan gene expression assays for
rat MOG, rat MBP, rat Egr2, mouse
EPOR and rat hypoxanthine phosphori-
bosyltransferase 1 (HPRT1, housekeeping
gene), commercially available from Ap-
plied Biosystems/Life Technologies. For
quantification, we used the comparative
threshold cycle (ΔΔCt) method, following
Applied Biosystems/Life Technologies
guidelines. Results were normalized to
HPRT1 expression and expressed as arbi-
trary units, using as a calibrator one of
the control samples, as specified in the
figure legends. Gene expression was con-
sidered undetectable when the threshold
cycle for fluorescence detection was >38.
Statistical significance was determined
using the unpaired two-tailed Student t
test or, for multiple comparisons, the
Dunnett or Tukey-Kramer test.
MOG Western Blot
CG4 and CG4-EPOR cells were plated
in poly-L-ornithine–coated petri dishes
in GM, differentiated by switching to
DM and treated with or without EPO.
Cells were collected and centrifuged, su-
pernatants were discarded and pellets
lysed in 50 μL of lysis buffer without
β-mercaptoethanol, as described (25).
Protein concentration was measured
using the BCA reagent kit (Pierce
Biotechnology, Rockford, IL, USA), and
100 μg of cellular proteins were ana-
lyzed by polyacrylamide gel electro -
phoresis. Separated proteins were blot-
ted using Trans-Blot Turbo Blotting
System (Bio-Rad, Hemel Hempstead,
Hertfordshire, UK) onto a polyvinyli-
denefluoride (PVDF) membrane. Mem-
branes were blocked overnight with 2%
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casein (Fisher Scientific, Loughborough,
Leicestershire, UK) in PBS, as reported
(25). Antibodies used were: mouse mon-
oclonal anti-MOG Z12 (kindly donated
by Gareth Pryce, ICMS, Queen Mary
University of London, UK), mouse anti-
β-actin (clone AC-15, #A54541) (Sigma-
Aldrich), goat anti-mouse IgG-HRP
(#3697) (Santa Cruz Biotechnology, Hei-
delberg, Germany). Protein bands were
visualized by exposing membranes de-
veloped with the ECL reagent (Amer-
sham/GE Healthcare Life Sciences, Little
Chalfont, Buckinghamshire, UK) to
chemiluminescence film  (Hyperfilm ECL)
(Amersham/ GE Healthcare Life Sci-
ences).
siRNA Transfection
CG4-EPOR cells were plated in GM
without penicillin and streptomycin. The
next day cells were switched to DM and
transfected with a Silencer Select Pre-
 designed Egr2-siRNA (s137448) (Ambion/
Life Technologies) or control siRNA
(Ambion/Life Technologies) using
lipofectamine RNAiMAX (Invitrogen/
Life Technologies), according to the man-
ufacturer’s instructions. After a further
24 h, the cells were treated with or with-
out EPO as indicated.
RESULTS
EPO Does Not Induce Myelin Gene
Expression in Wild-type CG4 Cells Not
Expressing EPOR
We first studied the effect of EPO on
MOG and MBP gene expression in wild-
type CG4 cells. Cells were differentiated
for 5 d in differentiation medium (DM)
with or without 80 ng/mL EPO. Differ-
entiation alone induced both MOG and
MBP gene expression by about nine-fold
compared with undifferentiated cells
(Figure 1). The addition of 80 ng/mL
EPO during the differentiation period
did not increase MOG or MBP gene ex-
pression compared with untreated cells
(see Figure 1). However, EPO receptor
(EPOR) was not detected in these cells by
qPCR analysis (fluorescence threshold
cycle for EPOR amplification was >38).
EPO Induces Myelin Gene Expression
in EPOR-Expressing CG4 Cells
EPOR expression in genetically modi-
fied CG4-EPOR cells was verified by
measuring the EGFP reporter expression
by flow cytometry, which showed that
90.2% of cells expressed the transgene
(Figure 2A). We then characterized the
expression of EPOR in CG4-EPOR cells
differentiated for 3, 6 and 9 d with or
without EPO by Western blot, using 
anti-V5-tag antibodies. EPOR was de-
tected in CG4-EPOR cells at all time
points (Figure 2B), and its expression
level was not affected by EPO.
Having established that EPOR was 
expressed, we then treated CG4-EPOR
cells with different concentrations of
EPO for 6 d during cell differentiation
and analyzed MOG and MBP mRNA. As
shown in Figure 3A–B, EPO, at concen-
trations of 8 ng/mL and higher, in-
creased MOG and MBP gene expression
by six- and three-fold respectively, com-
pared with untreated cells. Although no
further induction was found with doses
of 80 and 400 ng/mL, the intermediate
dose of 80 ng/mL was chosen for further
experiments since this dose is the most
used in neuroprotection studies (6). A
time-course experiment investigating the
effect of EPO at 80 ng/mL on MOG and
MBP mRNA expression in CG4-EPOR
cells is shown in Figure 3C–D. EPO in-
creased MOG (see Figure 3C) and MBP
(see Figure 3D) expression in differenti-
ated cells by two- to four-fold at all time
points analyzed.
Induction of MOG Protein Expression
by EPO
As all the above experiments were per-
formed analyzing the mRNA expression
for myelin genes, we sought confirmation
of the effect of EPO at the protein level. 
In preliminary experiments, we set up a
reliable detection of MOG protein by
Western blot. In the experiments shown in
Figure 4A, CG4-EPOR and wild-type cells
were differentiated with DM and treated
with or without 80 ng/mL EPO. MOG
protein expression was analyzed by West-
ern blot at 3, 6 and 9 d of differentiation in
CG4-EPOR cells and at d 9 in wild-type
CG4 cells. Western blot for β-actin was
used as a loading control (Figure 4).
The inducing effect of EPO on MOG
protein was very clear at 6 and 9 d in
CG4-EPOR cells. No induction was ob-
served in wild-type CG4 cells, confirm-
ing the results obtained by qPCR. We
then confirmed EPO-induced MOG pro-
tein increase in CG4-EPOR cells in an in-
dependent experiment (Figure 4B). MOG
protein was detectable at d 9 of differen-
tiation in the absence of EPO, but was in-
duced at higher levels upon incubation
with EPO for the whole differentiation
period (d 0–9), confirming the results of
the experiment shown in Figure 4A. This
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Figure 1. EPO does not increase myelin
gene expression in wild-type CG4 cells.
CG4 cells were plated in poly-L-ornithine–
coated 24 well plates in growth medium
(GM). After 2 d, cells were switched to dif-
ferentiation medium (DM) and cultured in
the absence or in the presence of EPO
80 ng/mL. At d 5 of differentiation MOG
(A) and MBP (B) gene expression were an-
alyzed by quantitative PCR (qPCR). Results
are expressed as arbitrary units versus un-
differentiated (UND) cells and are the
mean ± standard deviation (SD) of six
samples from two independent experi-
ments analyzed in duplicate. ***P < 0.001
versus UND cells by two-tailed unpaired
Student t test.
effect also was observed when the cells
where incubated with EPO on d 0–7 of
differentiation, whereas treatment with
EPO only on d 0–3 was less effective (see
Figure 4B). Therefore, EPO increased
MOG expression also at the protein level
in CG4-EPOR cells.
EPOR is Specifically Required by EPO
to Induce Myelin Genes
Because in the experiments reported
above we compared EPOR-expressing
CG4 cells obtained using a lentiviral vec-
tor with wild-type cells, we wanted to
ascertain that the observed differences
were actually due to expression of EPOR
and not to the vector itself.
We thus transduced CG4 cells with a
vector containing only EGFP (CG4-
EGFP), used as negative control. Cells
were differentiated for 5 d with DM and
treated with or without 80 ng/mL EPO
exactly as in the experiments described
above. Then, MOG expression was mea-
sured by qPCR. As shown in Figure 5A,
differentiation induced expression of
MOG but EPO was ineffective, in accord
with the results obtained in wild-type
CG4 cells (see Figure 1A). Thus, EPOR
expression is responsible for the effects
of EPO observed in CG4-EPOR cells.
To further confirm the requirement of
EPOR for EPO induction of myelin
genes, CG4-EPOR cells were cloned by
limiting dilution as described in the Ma-
terials and Methods section. Three clones
expressing differential levels of EPOR
(R9, R15 and R21; Figure 5B) were used
to study the effect of EPO on myelin
gene induction. Cells were differentiated
for 5 d with and without EPO and MOG
gene expression was measured by qPCR.
EPO did not have any effect in the low-
EPOR clone R9, but induced MOG
mRNA by 4.4-fold in the intermediate-
EPOR clone R15 and 8-fold in the high-
EPOR clone R21 and in the parental
CG4-EPOR line (Figure 5C). Therefore,
the MOG response to EPO was increased
as the level of EPOR expression in-
creased. Moreover, carbamylated EPO
(CEPO), that does not bind to the ho-
modimeric EPOR but is still cytoprotec-
tive and neuroprotective (18), did not
have any effect on MOG gene expression
in CG4-EPOR cells and in clone R21,
showing that in this model induction of
MOG likely occurs through the classical
EPOR (see Figure 5C). In conclusion,
MOG was not induced by EPO when
EPOR expression was low (in CG4-EGFP
cells [see Figure 5A] and in clone R9 [see
Figure 5C]), and was induced by EPO,
but not by CEPO (that does not bind the
EPOR dimer), when EPOR expression
was high (in CG4-EPOR cells and in
clone R21 [see Figure 5C]). Therefore, in
our in vitro system high EPOR expression
was necessary and sufficient to induce
MOG gene expression.
Egr2 is Induced by EPO but Does Not
Mediate EPO-Induced Increase of
Myelin Genes
We first investigated whether EPO in-
duces Egr2 gene expression in CG4-
EPOR cells. Based on our similar experi-
ments where Egr2 expression was
studied in EPOR-expressing neuronal
B104 cells (6), we exposed differentiated
CG4-EPOR cells to EPO for 1 h and Egr2
expression was measured by qPCR. EPO
induced Egr2 by about 20-fold compared
with untreated cells (Figure 6A).
To establish whether the observed up-
regulation of Egr2 has a role in the in-
duction of myelin genes by EPO, Egr2
was silenced with an Egr2-siRNA, upon
switching the cells to DM. After 1 d,
when EPO-induced Egr2 expression was
inhibited by 80% in Egr2-siRNA trans-
fected cells (Figure 6B), cells were treated
with or without EPO and MOG gene ex-
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Figure 2. EPOR expression in CG4-EPOR cells. (A) CG4 cells were transduced with a bi-
cistronic lentiviral vector expressing EPOR and EGFP and cultured in GM. The efficiency of
transfection in genetically modified (CG4-EPOR) cells was verified by measuring by flow
cytometry the EGFP reporter expression, whose translation is linked to EPOR via the internal
ribosome entry site (IRES). About 90% of the CG4-EPOR cells expressed EGFP, as opposed to
1.4% of background fluorescence in wild-type CG4 cells. The experiment is representative
of three experiments. EGFP expression in single experiments was 83%, 90.2% and 87.9%. (B)
CG4-EPOR were switched to DM and cultured for 3, 6 and 9 d with or without EPO. EPOR
expression during cell differentiation was confirmed by immunoblotting with anti-V5-tag
mouse antibody. As a negative control, wild-type CG4 cells at d 9 of differentiation also
were analyzed for transduced EPOR expression. The numbers on the left of the panel indi-
cate the positions of molecular weight markers of the indicated sizes in kDa.
pression was measured at d 4 of differen-
tiation. EPO significantly increased MOG
mRNA in CG4-EPOR cells nontrans-
fected (no siRNA) or transfected with a
control siRNA (by 11-fold and 10-fold, re-
spectively), as expected, and the EPO ef-
fect was not blocked by Egr2 silencing. In
fact, in the presence of Egr2-siRNA, EPO
still increased MOG expression by 8-fold
(Figure 6C).
Of note, Egr2 silencing induced MOG
by 2.7-fold as compared with nontrans-
fected cells; no induction was observed
using a control siRNA (see Figure 6C).
Therefore, EPO increased myelin gene
expression in CG4-EPOR cells by a sig-
naling pathway independent of Egr2.
Moreover, knocking down Egr2 expres-
sion promoted expression of MOG with
and without EPO stimulation, suggesting
that Egr2 might be a negative regulator
of MOG whose effect is overridden by
EPOR activation.
DISCUSSION
This study shows that EPO increases
the expression of myelin genes (MOG
and MBP) in differentiated CG4-EPOR
cells, and that this effect requires EPOR.
The induction of both myelin genes was
observed starting from an EPO concen-
tration of 8 ng/mL, was already detect-
able at d 2 and still present at d 6 of dif-
ferentiation The requirement for EPOR
was demonstrated by the lack of effect
of EPO in non-EPOR-expressing wild-
type cells or in cells transduced with
EGFP only in a lentiviral vector, and by
experiments showing that the effect of
EPO is smaller in clones expressing
lower EPOR levels. Interestingly, pri-
mary oligodendrocytes express low lev-
els of EPOR under physiological condi-
tions (15); however, EPOR is increased in
the central nervous system in patholo-
gies where EPO shows a protective 
effect (23,29).
To identify transcription factors impli-
cated in the effect of EPO on myelina-
tion, we focused on Egr2. Egr2 is induced
alongside with myelin genes in dorsal
root ganglia cells treated with IL-6,
which also stimulates myelination in vivo
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Figure 3. Dose-response and time-course of myelin gene expression in CG4-EPOR cells
upon EPO treatment. (A–B) CG4-EPOR cells were differentiated and treated with different
concentrations of EPO. MOG (A) and MBP (B) gene expression were analyzed by qPCR at
d 6 of differentiation. Results are expressed as arbitrary units versus untreated (no EPO)
cells and are the mean ± SD of six to nine samples from three independent experiments
analyzed in duplicate (panel A, MOG: no EPO, N = 9; EPO doses of 0.004 and 0.4 ng/mL,
N = 6; EPO doses of 8, 80 and 400 ng/mL, N = 9; panel B, MBP: no EPO, N = 6; EPO doses of
0.004 and 0.4 ng/mL, N = 6; EPO doses of 8, 80 and 400 ng/mL, N = 6). *P < 0.05; ***P <
0.001 versus no EPO by Dunnett’s method. (C–D) CG4-EPOR cells were differentiated and
treated with or without EPO 80 ng/mL. MOG (C) and MBP (D) gene expression were ana-
lyzed by qPCR at 2, 4 and 6 d of differentiation. The results are expressed as arbitrary units
versus undifferentiated (time 0) cells and are the mean ± SD of four to six samples from
two independent experiments analyzed in duplicate. *P < 0.05; **P < 0.01; ***P < 0.001
versus no EPO at the same time point by Student t test.
Figure 4. EPO increases MOG protein expression. CG4-EPOR (A and B) and wild-type CG4
cells (A) were differentiated with or without EPO. MOG protein expression (with β-actin as
loading control) was analyzed by Western blot at the indicated days of differentiation (A)
or at d 9 (B). The set of numbers along the left side of the images represents the position
of molecular weight markers of the indicated sizes in kDa.
(30,31). Since EPO shares structural simi-
larities with IL-6 (both are 4-α helical cy-
tokines), and we observed that Egr2 is
upregulated by EPO in models of cere-
bral ischemia (6), we asked whether Egr2
is involved in the induction of MOG and
MBP by EPO in CG4 cells. However, si-
lencing Egr2 gene expression in CG4-
EPOR cells by an Egr2-siRNA did not in-
hibit the effect of EPO on myelin gene
expression, indicating that Egr2 is not
implicated in the action of EPO on oligo-
dendrocytes. In fact, Egr2 silencing unex-
pectedly induced expression of myelin
genes per se. Therefore, it may well be
that Egr2 has an essential role in myeli-
nation only in the peripheral nervous
system, where indeed its deficiency re-
sults in severe demyelination (27).
It is possible that other signaling path-
ways are implicated in EPO/EPOR-
 induced myelination. For instance, the
survival kinase Akt has a key role in the
neuroprotective action of EPO (32) and it
has also been reported to promote myeli-
nation in the CNS (33).
CONCLUSION
The direct effect of EPO on myelina-
tion in oligodendrocytes reported here is
further evidence that EPO, in addition to
cytoprotective and antiinflammatory ac-
tions, can promote myelin repair. In
terms of repair, increased expression of
myelin genes might contribute to the
overall effect of EPO, along with preven-
tion of oligodendrocyte cell death (34,35),
stimulation of neurogenesis and angio-
genesis (4), and induction of neuronal
plasticity (6). This might be relevant to
demyelinating diseases, and it is interest-
ing to note that EPO is effective not only
in animal models of MS but also in a
pilot clinical trial (36). Furthermore, in-
duction of myelin genes, together with
promotion of oligodendrogenesis, might
play a role in EPO-induced neurological
recovery in stroke as well as in neonatal
hypoxic-ischemic brain injury, where
oligodendrocyte damage is an important
pathogenic component (5,37–39).
Our experiments using CG4 cells engi-
neered to express EPOR provide a clear
demonstration that EPOR can mediate at
least some of the reparative effects of
EPO in nonerythroid cells and that EPO-
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Figure 5. EPO effect is dependent on EPOR
expression. (A) EPO has no effect in CG4
cells transduced with the EGFP vector. CG4
cells transduced with EGFP (CG4-EGFP)
were differentiated and treated with or with-
out EPO 80 ng/mL. MOG gene expression
was analyzed by qPCR at d 5 of differentia-
tion. Results are expressed as arbitrary units
versus undifferentiated (UND) cells and are
the mean ± SD of four samples analyzed in
duplicate. **P < 0.05 versus UND cells by Stu-
dent t test. (B-C) EPO increases MOG expres-
sion in a receptor-dependent manner. (B) Ex-
pression of EPOR in three CG4-EPOR clones
(R9, R15 and R21) isolated by plating the
cells at clonal densities. EPOR expression was
measured by qPCR in quadruplicate sam-
ples analyzed in duplicate and expressed as
arbitrary units versus EPOR expression in the
CG4-EPOR cell line. *P < 0.05 by Tukey-
Kramer’s test. (C) CG4-EPOR cells and R9,
R15 and R21 cell clones were differentiated
in the absence or in the presence of EPO 80
ng/mL; CG4-EPOR and R21 were also differ-
entiated in the presence of carbamylated
EPO (CEPO) at 80 ng/mL. MOG gene ex-
pression was analyzed by qPCR at d 5 of dif-
ferentiation. Results are expressed as arbi-
trary units versus no EPO and are the mean
± SD of four samples analyzed in duplicate.
***P < 0.001 versus no EPO by Student t test.
Figure 6. EPO does not act through Egr2 to
increase myelin gene expression. (A) EPO
induces Egr2 gene expression in CG4-EPOR
cells. CG4-EPOR cells were plated in GM,
then switched to DM and after 24 h treated
with or without EPO 80 ng/mL for 1 h. Egr2
expression was measured by qPCR. Results
are expressed as arbitrary units versus no
EPO and are the mean ± SD of nine to
twelve samples analyzed in duplicate (no
EPO, N = 9; EPO, N = 12). ***P < 0.001 versus
no EPO by Student t test. (B–C) EPO effect
on MOG expression is not blocked by Egr2
silencing. CG4-EPOR cells were differenti-
ated and transfected with siRNA targeting
Egr2 or with a negative control siRNA. After
24 h cells were treated with or without EPO
80 ng/mL. Egr2 gene expression was mea-
sured 1 h after EPO stimulation (B) and
MOG was measured at d 4 of differentia-
tion (C). Results are expressed as arbitrary
units versus control cells (no siRNA, no EPO)
and are the mean ± SD of four to six sam-
ples analyzed in duplicate (panel B, N = 4;
panel C, N = 6). ***P < 0.001 versus no EPO;
§P < 0.001 versus no siRNA; #P < 0.001 versus
control siRNA; Student t test.
EPOR interaction can induce effects
other than the erythropoietic ones.
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